Related news from
Tue, 09 Apr 2024 13:00:00 +0000	Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO,
Mon, 25 Mar 2024 17:28:23 +0000	Investing in Harvard Bioscience (NASDAQ:HBIO) a year ago would have delivered you a 25% gain It hasn't been the best quarter for Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shareholders, since the share price has...
Tue, 12 Mar 2024 14:30:00 +0000	Sidoti Events, LLC's Virtual March Small-Cap Conference NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 13-14, ...
Mon, 11 Mar 2024 12:00:00 +0000	Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company’s Chief Financial Officer. Both presentations will be webcast live and can be accessed through the investor relations section
Sat, 09 Mar 2024 12:34:08 +0000	Is There An Opportunity With Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 34% Undervaluation? Key Insights The projected fair value for Harvard Bioscience is US$6.70 based on 2 Stage Free Cash Flow to Equity...
Fri, 08 Mar 2024 15:48:35 +0000	Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2023 Earnings Call Transcript Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2023 Earnings Call Transcript March 7, 2024 Harvard Bioscience, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and thank you for standing by. Welcome to Harvard Bioscience, Inc. Fourth Quarter 2023 Earnings […]
Fri, 08 Mar 2024 03:51:08 +0000	Q4 2023 Harvard Bioscience Inc Earnings Call Q4 2023 Harvard Bioscience Inc Earnings Call
Thu, 07 Mar 2024 18:56:16 +0000	Harvard Bioscience Inc (HBIO) Reports Mixed Fourth Quarter and Full Year 2023 Results Modest Revenue Decline with Significant Gross Margin Expansion Amidst APAC Challenges
Thu, 07 Mar 2024 12:00:00 +0000	Harvard Bioscience Announces Fourth Quarter 2023 Financial Results Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating income of $3.3 millionStrong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023. Jim Green, Chairma
Wed, 06 Mar 2024 13:30:00 +0000	Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analyticsHOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing prec
Tue, 27 Feb 2024 22:10:00 +0000	Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio
Wed, 31 Jan 2024 11:03:49 +0000	Several Insiders Invested In Harvard Bioscience Flagging Positive News It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Mon, 20 Nov 2023 21:40:00 +0000	Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023 HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Jim Green, Chairman and Chief Executi
Mon, 20 Nov 2023 16:35:42 +0000	With 60% ownership, Harvard Bioscience, Inc. (NASDAQ:HBIO) boasts of strong institutional backing Key Insights Significantly high institutional ownership implies Harvard Bioscience's stock price is sensitive to their...
Thu, 09 Nov 2023 21:30:00 +0000	Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023 HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer. The Company’s presentation will begin at 9:40 AM ET / 8:40 AM CT on November 16th. A replay of the presentation will be
Thu, 09 Nov 2023 19:28:18 +0000	Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2023 Earnings Call Transcript Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2023 Earnings Call Transcript November 7, 2023 Harvard Bioscience, Inc. misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.04. Operator: Thank you for standing by and welcome to the Harvard Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today’s program is being recorded. […]
Wed, 08 Nov 2023 02:58:25 +0000	Q3 2023 Harvard Bioscience Inc Earnings Call Q3 2023 Harvard Bioscience Inc Earnings Call
Tue, 07 Nov 2023 13:00:09 +0000	Harvard Bioscience Inc (HBIO) Reports Q3 2023 Earnings: Gross Margin Expands Amid Revenue Decline Despite a 6% revenue decline, the company's gross margin improved significantly year-over-year
Tue, 07 Nov 2023 12:00:00 +0000	Harvard Bioscience Announces Third Quarter 2023 Financial Results Q3 Revenues of $25.4 millionQ3 Gross Margin of 58.1%Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 millionContinued strong operating cash flow drove debt reduction of $8.3 million through Q3 HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023. Jim Green, Chairman and CEO said, “Overall, I’m encouraged to see solid year-over-year third qu
Mon, 06 Nov 2023 21:30:00 +0000	Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023 Innovative solutions for academic, CRO, pharma and biotech customersHOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused research and therap